Clinical Trials on Recurrent Grade 3 Follicular Lymphoma in Colombia

Total 136 results

National Cancer Institute (NCI)
Celgene Corporation

Active, not recruiting

Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma

Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditions

United States
National Cancer Institute (NCI)

Completed

Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma

Grade 3a Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage III Grade 3 Follicular Lymphoma | Ann Arbor Stage...

United States
National Cancer Institute (NCI)

Active, not recruiting

Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular Lymphoma | Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides | Recurrent Primary Cutaneous... and other conditions

United States, Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Gilead Sciences; Celgene Corporation

Completed

Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma

Recurrent Follicular Lymphoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Lymphoproliferative Disorder | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Grade 3 Follicular... and other conditions

United States, Canada, Australia, Puerto Rico
Morphotek
National Cancer Institute (NCI); Children's Oncology Group

Completed

MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Unspecified Childhood Solid Tumor, Protocol Specific | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma and other conditions

United States
CTI BioPharma

Completed

Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant (PIX-R)

Diffuse Large B-cell Lymphoma | de Novo DLBCL | DLBCL Transformed From Indolent Lymphoma | Follicular Grade 3 Lymphoma

United States, Germany, Italy, United Kingdom, Hungary, France, Spain, Ukraine, Czechia, Austria, Belgium, Bulgaria, Denmark, Poland, Romania, Russian Federation, Slovakia
National Cancer Institute (NCI)

Active, not recruiting

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

Glioblastoma | WHO Grade 3 Glioma | Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Glioma | Recurrent Cholangiocarcinoma | WHO Grade 2 Glioma

United States
Georgetown University
AbbVie; Pharmacyclics LLC.; Hackensack Meridian Health

Active, not recruiting

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Relapsed Follicular Lymphoma | Refractory Follicular Lymphoma

United States
Millennium Pharmaceuticals, Inc.

Completed

A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma (VERTICAL)

Follicular Lymphoma

United States
Gilead Sciences

Terminated

Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma

Follicular Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
National Cancer Institute (NCI)

Completed

MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

Unspecified Childhood Solid Tumor, Protocol Specific | Chronic Myelomonocytic Leukemia | Juvenile Myelomonocytic Leukemia | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone... and other conditions

United States, Canada
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Mosunetuzumab in People With Follicular Lymphoma

Lymphoma | Follicular Lymphoma

United States
University of California, San Francisco
BeiGene USA, Inc.; Pacific Pediatric Neuro-Oncology Consortium

Recruiting

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas (PNOC017)

Glioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent WHO Grade III Glioma | WHO Grade III Glioma | IDH2 Gene Mutation | IDH1 Gene Mutation | Low Grade Glioma | Recurrent WHO Grade II Glioma | WHO Grade II Glioma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas

Malignant Glioma | WHO Grade 3 Glioma | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Refractory Primary Central Nervous System Neoplasm | Recurrent Childhood Central Nervous System Neoplasm | Recurrent Brain Neoplasm | Recurrent Childhood...

United States
National Cancer Institute (NCI)

Recruiting

A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

Recurrent WHO Grade 2 Glioma | Recurrent Low Grade Astrocytoma | Refractory Low Grade Astrocytoma | Refractory Low Grade Glioma | Refractory WHO Grade 1 Glioma

United States, Canada
Epizyme, Inc.

Completed

Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL

B-cell Lymphomas (Phase 1) | Advanced Solid Tumors (Phase 1) | Diffuse Large B-cell Lymphoma (Phase 2) | Follicular Lymphoma (Phase 2) | Transformed Follicular Lymphoma | Primary Mediastinal Large B-Cell Lymphoma

Australia, Canada, France, Germany, Italy, Poland, Taiwan, Ukraine, United Kingdom, United States
National Cancer Institute (NCI)

Completed

Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy

HIV Infection | Clear Cell Renal Cell Carcinoma | Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell... and other conditions

United States
Lymphoma Study Association
Institute of Cancer Research, United Kingdom; Australasian Leukaemia and Lymphoma... and other collaborators

Completed

Primary Rituximab and Maintenance

Follicular Lymphoma

France, Thailand, Belgium, Spain, Argentina, Australia, Brazil, Colombia, Denmark, Netherlands, New Zealand, Peru
Biogen

Completed

Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)

Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
Ascenta Therapeutics

Completed

Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma

Follicular Lymphoma

United States
University of California, San Francisco
Novartis Pharmaceuticals; Pediatric Brain Tumor Foundation; The Lilabean Foundation...

Recruiting

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

High Grade Glioma | Low-grade Glioma | Recurrent World Health Organization (WHO) Grade II Glioma

United States
Kite, A Gilead Company

Completed

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1)

Relapsed Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B Cell Lymphoma (DLBCL) | Transformed Follicular Lymphoma (TFL) | Primary Mediastinal B-cell Lymphoma (PMBCL) | High Grade B-cell Lymphoma (HGBCL)

United States, Netherlands, Canada, France, Germany, Israel
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Adult Non-Hodgkin Lymphoma | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Non-Hodgkin Lymphoma

United States, Canada, Puerto Rico, Australia, Switzerland
The Lymphoma Academic Research Organisation
Celgene Corporation

Active, not recruiting

A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma (RELEVANCE)

Follicular Lymphoma

Spain, Canada, France, Australia, Italy, Belgium, Germany, Portugal
Sabine Mueller, MD, PhD
Pacific Pediatric Neuro-Oncology Consortium

Recruiting

Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults

Glioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent Grade III Glioma | Grade III Glioma

United States, Australia, Israel, Switzerland
Kite, A Gilead Company

Recruiting

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma (ZUMA-22)

Relapsed/Refractory Follicular Lymphoma

United States, Spain, United Kingdom, Italy, France, Japan, Germany
National Cancer Institute (NCI)

Completed

Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy

Childhood High-grade Cerebellar Astrocytoma | Childhood High-grade Cerebral Astrocytoma | Recurrent Childhood Anaplastic Astrocytoma | Recurrent Childhood Anaplastic Oligoastrocytoma | Recurrent Childhood Anaplastic Oligodendroglioma | Recurrent Childhood Cerebellar Astrocytoma | Recurrent Childhood... and other conditions

United States, Canada
Hoffmann-La Roche

Completed

A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma

United States, Spain, United Kingdom
Hoffmann-La Roche
AbbVie

Completed

A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)

Follicular Lymphoma

United States, Italy, Canada, Australia, Belgium, United Kingdom, Germany, France
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-Cell Lymphoma, Lymphoma Follicular

United States, Australia, Italy
Canadian Cancer Trials Group
Pfizer

Completed

Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours

Refractory Lymphoma | Recurrent Lymphoma | Solid Tumours | Central Nervous System

Canada
NCIC Clinical Trials Group

Completed

Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma

Lymphoma

Canada
University of California, San Francisco
Novartis Pharmaceuticals; Pacific Pediatric Neuro-Oncology Consortium; The Pediatric...

Active, not recruiting

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

Pediatric Recurrent Progressive Low-grade Gliomas | Pediatric Progressive Low-grade Gliomas

United States
AIDS Malignancy Consortium
National Cancer Institute (NCI)

Recruiting

Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers

HIV Infection | Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Lymphoma | Multicentric Castleman Disease | Plasmablastic Lymphoma | Kaposi Sarcoma | Recurrent Lymphoma | Anal Carcinoma | Recurrent Kaposi Sarcoma | Recurrent Plasmablastic Lymphoma | Transplant-Related Kaposi Sarcoma

United States
Sandoz
Novartis Pharmaceuticals

Completed

GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL) (ASSIST_FL)

Follicular Lymphoma

Russian Federation, Netherlands, Peru, United Kingdom, Romania, Brazil, Malaysia, Spain, India, Italy, Bulgaria, Poland, South Africa, Japan, Argentina, Australia, Austria, Colombia, France, Germany, Greece, Hungary, Ireland, Israel, Po... and more
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Recurrent B Lymphoblastic Lymphoma | Refractory B Lymphoblastic Lymphoma

United States, Puerto Rico
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma

Lymphoma

United States
Hoffmann-La Roche

Completed

A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkin's Lymphoma

France, Italy, Australia, Canada, Sweden, Switzerland
Genmab
AbbVie

Recruiting

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1)

Follicular Lymphoma (FL)

Austria, Greece, Israel, Korea, Republic of, Spain, Hungary, Sweden, Switzerland, France, Poland, Taiwan, Australia, Denmark, New Zealand, Turkey, Italy, Netherlands, Belgium, Canada, South Africa, Czechia, Brazil, Germany, Argentina, United... and more
Genmab
AbbVie

Recruiting

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

Diffuse Large B-Cell Lymphoma | Classic Follicular Lymphoma

United States, Puerto Rico
Gilead Sciences

Completed

Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas (DELTA)

Follicular Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Small Lymphocytic Lymphoma

United States, United Kingdom, Italy, Germany, Poland, France
Incyte Corporation

Active, not recruiting

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (InMIND)

Follicular Lymphoma | Marginal Zone Lymphoma

Finland, United States, Spain, Korea, Republic of, Canada, Israel, Turkey, United Kingdom, Netherlands, Greece, Italy, France, Taiwan, Germany, Belgium, Japan, Czechia, Switzerland, Ireland, Poland, Ukraine, Australia, Denmark, Hungary, Swede... and more
Kite, A Gilead Company

Active, not recruiting

A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5)

Follicular Lymphoma | Marginal Zone Lymphoma | Indolent Non-Hodgkin Lymphoma

United States, France
National Cancer Institute (NCI)

Completed

Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma

Recurrent Adult Hodgkin Lymphoma | Refractory Childhood Hodgkin Lymphoma | Recurrent Childhood Hodgkin Lymphoma

United States, Canada
National Cancer Institute (NCI)

Completed

Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Recurrent Adult Lymphoblastic Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | B-cell Adult Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood... and other conditions

United States, Canada, Australia, Puerto Rico
Genentech, Inc.

Completed

A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (ROMULUS)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma

United States, Canada, France, Italy, Germany, Netherlands
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

Osteosarcoma | Lymphoblastic Lymphoma | Recurrent Lymphoma | Recurrent Malignant Neoplasm | Hodgkin Lymphoma in Remission | Leukemia in Remission | Recurrent Leukemia

United States, Australia, Canada, Puerto Rico

Clinical Trials on Recurrent Grade 3 Follicular Lymphoma in Colombia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations